Left atrial appendage occlusion device infection: Take it or leave it?
Luai Madanat, MD,* Richard Bloomingdale, MD,† Kuldeep Shah, MD,† Amal Khalife, DO,‡ David E. Haines, MD, FHRS,† Nishaki K. Mehta, MD, FHRS†

From the *Department of Internal Medicine, William Beaumont Hospital – Royal Oak, Royal Oak, Michigan, †Department of Cardiovascular Medicine, William Beaumont Hospital – Royal Oak, Royal Oak, Michigan, ‡Department of Infectious Disease, William Beaumont Hospital – Royal Oak, Royal Oak, Michigan, §Oakland University School of Medicine. Rochester, Michigan, and ‡University of Virginia, Charlottesville, Virginia.

Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its prevalence is expanding owing to advanced age and higher rates of chronic heart disease.1 The standard treatment for stroke reduction in patients with nonvalvular AF is anticoagulation. However, alternative therapy may be advisable in a certain subset of patients, owing to either previous failure of oral anticoagulation or presence of contraindications to anticoagulation.1

The left atrial appendage has been identified as the primary site of thrombus formation in more than 90% of patients with AF.2 The PLAATO3 study in 2002 was the first to demonstrate the use of a device to occlude the left atrial appendage for stroke reduction in patients with AF and provided the fundamental ground for future development in that field. Since its publication several percutaneous left atrial appendage occlusion (LAAO) devices have been developed and tested, including the Watchman, Amulet, and LARIAT, among others.4 The Watchman (Boston Scientific, Marlborough, MA) is the most extensively studied and is the only FDA-approved percutaneous LAAO device currently available in the United States.5 More than 100,000 devices have been implanted since it gained its approval in 2015.6

LAAO devices are approved for use in patients with nonvalvular AF who are not candidates for long-term coagulation with comparable outcomes in terms of risk of stroke, bleeding, and cardiovascular complications.7,8 Percutaneous LAAO has also been used in patients with recurrent cardioembolic stroke while on oral anticoagulation.9

Implantation of any intracardiac device carries the risk of device thrombosis and infection. However, risk of LAAO device infection is low owing to complete endothelialization. Currently, there are no guidelines regarding prophylaxis of bacterial endocarditis with Watchman device placement. Similarly, management of LAAO device infections remains uncertain, with no clear guidelines. We report a case of a 74-year-old man with Watchman device infection that was managed conservatively with a long course of antibiotics without the need for surgical extraction.

Case report
A 74-year-old man with a past medical history significant for persistent AF with history of LAAO device implantation 12 months prior owing to stroke while on apixaban (CHA2DS2-VASc score of 4, HAS-BLED score of 3), prostate cancer status post radiation therapy, and metastatic melanoma on intravenous pembrolizumab via a right subclavian central intravenous catheter presented to the emergency center with symptoms of fatigue, myalgias, fever, and cough. He was febrile (101°F), hypotensive (81/53 mm Hg), and in AF

KEY TEACHING POINTS
- Left atrial appendage occlusion devices, despite endothelialization, can carry a late risk of device-related infective endocarditis.
- Review of literature suggests role of transesophageal echocardiogram in the diagnosis of left atrial appendage occlusion device infections.
- While surgical extraction has been previously described, we report a case of successful antibiotic suppression at 6-month follow-up.
with rapid ventricular response and heart rate of 120 beats per minute. Work-up revealed mild anemia with hemoglobin of 9.6 g/dL and thrombocytopenia with platelet count of 1.47 × 10^9/L. Cardiac-sensitive troponin was mildly elevated at 0.11 ng/mL, but then normalized following intravenous fluid resuscitation. Procalcitonin was elevated at 3.20 ng/mL. COVID swab was negative. Extensive work-up including pan computed tomography scan failed to reveal an infectious source. Blood cultures were obtained and he was started on broad-spectrum intravenous (IV) antibiotics for presumptive pneumonia given his elevated procalcitonin.

Blood cultures grew methicillin-sensitive Staphylococcus aureus and antibiotics were narrowed from vancomycin and piperacillin-tazobactam to cefazolin based on susceptibility results. The central venous catheter was removed. A transthoracic echocardiogram was obtained and no valvular or device vegetations were identified. Repeat sets of blood cultures obtained on days 3 and 5 were persistently positive for Staphylococcus aureus despite targeted antibiotic therapy and removal of the indwelling venous catheter. The following day the patient underwent transesophageal echocardiogram (TEE), which demonstrated an appropriately seated LAAO device with a mobile echodensity measuring 1.35 × 0.45 cm attached to the device, which was consistent with a vegetation in this clinical context (Figures 1 and 2). The antibiotic regimen was modified to nafcillin and rifampin combination therapy for device-related endocarditis. Given the patient’s comorbidities and high procedural risk, a multidisciplinary team including cardiothoracic surgery, cardiology, infectious disease, oncology, and the patient decided to continue with nonoperative therapy. Consecutive repeat blood cultures on days 7 and 9 were sterile. Over the course of his stay, the patient clinically improved without fever or hemodynamic instability. He developed acute kidney injury owing to nafcillin-related acute interstitial nephritis. His antibiotic therapy was changed to cefazolin and subsequently to vancomycin after renal function improved. The patient was discharged from the hospital on IV vancomycin and oral rifampin for 6 weeks. At the time of follow-up 6 weeks later, intravenous antibiotics were stopped and he was treated with oral cefalexin for lifelong suppressive therapy. On clinical follow-up at 6 months, he continues to fare well, with no recurrent hospitalizations for infection.

In our case, the patient presented well outside the window of endothelialization and 30-day postimplant TEE confirmed that the device was well seated and healed in the left atrial appendage with minimal residual leak (1.5 mm) and iatrogenic aneurysmal interatrial septum with right-to-left shunting (Figure 1).
Discussion

We present a rare and unique case of an LAAO device–related infection 12 months following implantation in a patient with sepsis and persistent bacteremia despite appropriate IV antibiotics. No alternative source for sepsis was identified and removal of his central venous catheter did not result in clearing of the bacteremia. As demonstrated in our case, initial testing with transthoracic echocardiogram may be insensitive for detection of device-related vegetations. Therefore, a high degree of clinical suspicion should be maintained by physicians when a patient with a cardiac device presents with an infection, regardless of the timeline.

Risk of LAAO device infections is presumed to be highest during the first 45 days following implantation, after which complete endothelialization has likely occurred. According to most recent guidelines, TEE is recommended in patients with clinical suspicion of infective endocarditis when a prosthetic heart valve or intracardiac device is present (class I recommendation). Although the ability to differentiate thrombus and vegetations may prove difficult with echocardiography alone, the patient’s clinical presentation must also be considered. Guidelines for treating LAAO device infections are lacking; in our patient, we adopted the standard treatment for prosthetic valve endocarditis. The patient was successfully treated with a 6-week course of IV vancomycin in addition to oral rifampin. Ideally, he should have received IV gentamicin for the first 2 weeks, but given his age and comorbidities, risk of renal toxicity was a limiting factor.

Cardiac implantable electronic devices have been increasingly utilized for a variety of medical conditions owing to technological advances and acceptable or superior outcomes to alternative management strategies. However, increased number of device implantations necessarily results in increased prevalence of complications including device-related infections. Mortality from cardiac implantable electronic device infections is reported to occur in 16%–23% of patients at 12 and 24 months, respectively. While data are lacking for LAAO devices, we speculate similar mortality rates. Despite increased use of LAAO devices, cases of device infections are rarely reported in literature. The first case of a Watchman device infection was reported within 1 week of implantation in a patient who, similar to our case, failed to clear his bacteremia despite continuous IV antibiotics. Another report demonstrated a patient to have developed a Watchman device infection more than 2 years after implantation. Despite surgical extraction of the device, he died 3 days later from cardiogenic shock. Recently, Jensen and colleagues demonstrated a case of an infected Watchman treated with surgical extraction. None of these cases mentioned periprocedural antibiotic administration. In all previous cases of LAAO device infections, patients were managed with surgical extraction of the device. One of 3 patients died and the other 2 were doing well at 6-month and 10-month follow-up (Table 1). Our case is unique in that it is the only reported case demonstrating success of chronic antibiotic suppressive therapy at 6-month follow-up.

| Study/publication         | Age | Sex | Presentation at index hospitalization | Likely source of infection | Detection of device infection by TTE | Utilization of TEE | Time since Watchman implantation | Anticoagulation/antiplatelets at time of presentation | Causative microorganism | Management of device infection | Follow-up |
|---------------------------|-----|-----|--------------------------------------|---------------------------|-------------------------------------|-------------------|----------------------------------|---------------------------------------------------|-------------------------|---------------------------------|-----------|
| Jensen et al              | 74  | Male| Fever/sepsis                         | Diverticulitis            | No                                  | Yes                | 5 months                         | Aspirin, prasugrel                         | Enterobacter/Enterococcus               | Surgical extraction            | 10 months |
| Khumri et al              | 75  | Female| Sepsis/persistent bacteremia         | Peri-implantation bacteremia | N/A                                 | Yes                | Within 1 week                    | Warfarin                                   | Staphylococcus aureus               | Surgical extraction and 6 weeks of IV antibiotics | 6 months |
| Boukobza et al            | 83  | Male| Sepsis/subarachnoid hemorrhage        | Recent blood transfusion vs endophthalma | Yes                                 | Yes                | 30 months                        | Aspirin                                       | Pseudomonas aeruginosa            | Surgical extraction            | 6 months |
| Madanat et al (current study) | 74  | Male| Sepsis/persistent bacteremia         | Central venous catheter, immunosuppression | No                                  | Yes                | 12 months                        | None                                           | Methicillin-sensitive Staphylococcus aureus | 6 weeks of IV antibiotics + Rifampin followed by lifelong oral suppressive therapy | 6 months |

IV = intravenous; TEE = transesophageal echocardiogram; TTE = transthoracic echocardiogram; N/A = not available.
There are no clear guidelines regarding infection prophylaxis in patients undergoing placement of LAAO devices, given the rarity of this complication. Antibiotic prophylaxis during the period of device endothelialization and for 6 months following implantation have been expert opinion based, without clear consensus. Management of device infection also poses an area of uncertainty owing to lack of high-quality evidence and anecdotal reports. With expanding indications for LAAO device implantation, it is anticipated that device infection will become more prevalent.

**Conclusion**

LAAO device–related infections remain a rarely reported complication despite increased device implantations. Currently, there are no clear guidelines on the need for or duration of antibiotic prophylaxis following device placement nor the treatment options in case of device infection. At this time, management of patients should be individualized and tailored according to each patient. The treatment plan should be taken after a multidisciplinary discussion with the patient and essential personnel, including cardiothoracic surgery and infectious disease consultants.

**References**

1. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011;57:e101–e198.
2. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:755–759.
3. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887–1889.
4. Feldmann KJ, Arshi A, Yakubov SJ. An overview of left atrial appendage occlusion devices. Curr Cardiol Rep 2015;17:22.
5. Reddy VY, Mobius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013;61:2551–2556.
6. Jensen J, Thaler C, Saxena R, et al. Transesophageal echocardiography to diagnose Watchman device infection. CASE (Phila) 2020;4:189–194.
7. Holmes DR Jr, Alkhouli M, Reddy V. Left atrial appendage occlusion for the unmet clinical needs of stroke prevention in nonvalvular atrial fibrillation. Mayo Clin Proc 2019;94:864–874.
8. Camm AJ, Lip GY, De Caterina R, et al. Guidelines ESCCfP. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719–2747.
9. Spina R, Subbiah R, Markus R, Gunalingam B. Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation. Heart Lung Cir 2014;23:171–173.
10. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075–3128.
11. Piper C, Korfer R, Horstkotte D. Prosthetic valve endocarditis. Heart 2001;85:590–593.
12. Wilkoff BL, Boriani G, Mittal S, et al. Impact of cardiac implantable electronic device infection: a clinical and economic analysis of the WRAP-IT Trial. Circ Arrhythm Electrophysiol 2020;13:e008280.
13. Khumri TM, Thibodeau JB, Main ML. Transesophageal echocardiographic diagnosis of left atrial appendage occluder device infection. Eur J Echocardiogr 2008;9:565–566.
14. Boukobza M, Smaali I, Duval X, Laissy JP. Convexity subarachnoid hemorrhage, pseudomonas aeruginosa (PA) infective endocarditis and left atrial appendage occluder (LAAO) device infection. A case report. Open Neuroimag J 2017;11:26–31.